Japan Point-of-Care Diagnostics Market Surges from US$ 832.04 Million to US$ 1.93 Billion by 2033 as Decentralized Healthcare and Chronic Disease Testing Expand

The Japan Point-of-Care Diagnostics Market reached US$ 832.04 million in 2024 and is projected to grow to US$ 1,925.62 million by 2033, expanding at a CAGR of 9.8% during 2025-2033. Growth is being fueled by increasing demand for rapid medical testing, rising chronic disease prevalence, and the shift toward decentralized healthcare across Japan. The market is also benefiting from advancements in portable diagnostic technologies and stronger emphasis on early detection and timely clinical decision-making.

Point-of-care diagnostics enables testing at or near the site of patient care, delivering fast and reliable results without the need for centralized laboratories. These solutions support immediate diagnosis, treatment adjustments, and improved patient outcomes, particularly in emergency care, home healthcare, and remote clinical settings. As innovations in microfluidics, biosensors, and digital connectivity continue to enhance test accuracy and convenience, point-of-care diagnostics is transforming healthcare delivery in Japan by making testing more accessible, efficient, and patient-centered.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/japan-point-of-care-diagnostics-market?sai-v

Japan Point-of-Care Diagnostics Market refers to the industry that provides rapid, portable diagnostic tests used in clinics, pharmacies, and homes to enable quick medical decision-making in Japan.

Key Developments

Japan
✅ April 2025: Japan's POC diagnostics market grew as clinics and hospitals expanded adoption of rapid testing systems to support decentralized patient management.

✅ February 2025: Japan recorded significant demand for POC tests for infectious diseases, supported by a market value of over USD 2.36 billion in 2024 and strong growth expectations through 2033.

United States
✅ July 2025: U.S. hospitals expanded deployment of rapid molecular POC platforms, including portable PCR analyzers, to accelerate infectious disease diagnosis in emergency departments and urgent care centers.

✅ May 2025: Pharmacies across the U.S. increased adoption of connected POC testing devices for chronic disease screening, enabling real-time reporting to clinicians and insurers.

✅ March 2025: Several U.S. diagnostic manufacturers launched upgraded lateral-flow and immunoassay-based POC tests tailored for cardiovascular and metabolic disease detection.

Mergers & Acquisitions

United States
✅ June 2025: A major U.S. diagnostics company acquired a POC molecular testing startup to expand its rapid PCR product portfolio and strengthen market competitiveness.

✅ April 2025: A U.S.-based health-tech firm partnered with retail healthcare chains to integrate AI-enabled analytics into POC diagnostic devices, improving diagnostic accuracy and faster result interpretation.

Key Players:
Becton, Dickinson and Company (BD) | Quidel Corporation | QIAGEN | Trinity Biotech | BioMérieux SA | Roche Diagnostics | Siemens Healthineers | Abbott Laboratories | Danaher Corporation | SEKISUI MEDICAL CO., LTD.

Key Highlights:
• Abbott Laboratories - Holds 15.8% share of the Japan point-of-care diagnostics market, supported by its strong portfolio in rapid testing, glucose monitoring, and infectious disease diagnostics.

• Roche Diagnostics - Accounts for 14.6% share, driven by advanced molecular point-of-care systems and high adoption of rapid immunoassays across hospitals and clinics.

• Siemens Healthineers - Maintains 13.2% share, propelled by its portable analyzers, critical-care POCT systems, and expanding decentralized testing solutions.

• Becton, Dickinson and Company (BD) - Holds 11.9% share, backed by POCT platforms for blood testing, infectious diseases, and safety-engineered diagnostic solutions.

• Danaher Corporation - Contributes 10.7% share, supported by its rapid molecular diagnostic technologies and handheld POCT devices through its diagnostics subsidiaries.

• QIAGEN - Holds 8.4% share, driven by rapid molecular diagnostic kits and point-of-care nucleic-acid testing platforms.

• Quidel Corporation - Accounts for 7.3% share, supported by strong demand for rapid antigen, immunoassay, and influenza testing kits.

• BioMérieux SA - Maintains 6.1% share, fueled by POCT solutions for infectious diseases and decentralized clinical testing.

• SEKISUI MEDICAL CO., LTD. - Holds 5.4% share, strengthened by domestic manufacturing of rapid diagnostic tests and localized assay development.

• Trinity Biotech - Contributes 3.6% share, driven by rapid immunodiagnostic kits for diabetes monitoring and infectious disease screening.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=japan-point-of-care-diagnostics-market?sai-v
(Purchase 2 or more Reports and get 50% Discount)

Market Drivers
• Growing need for rapid diagnostic solutions in emergency care, ICUs, and clinics is accelerating adoption of point-of-care (PoC) testing.

• Rising prevalence of chronic diseases, including diabetes, cardiovascular disorders, and respiratory conditions, is boosting demand for portable and real-time testing devices.

• Increasing focus on early disease detection and preventive healthcare is driving the uptake of at-home PoC kits.

• Strong government push toward healthcare digitalization and decentralized diagnostics is supporting wider integration of PoC systems across hospitals and community health settings.

• Expansion of Japan's geriatric population is increasing use of PoC diagnostics for quick monitoring of age-related conditions.

Industry Developments
• September 2025: Japanese diagnostic companies launched next-generation PoC testing platforms for infectious diseases with improved sensitivity and faster turnaround times.

• July 2025: Collaborations between medical device manufacturers and hospitals accelerated development of AI-supported PoC analyzers for chronic disease management.

• May 2025: Government programs promoted adoption of portable PCR-based PoC devices in rural and remote clinics to enhance access to rapid diagnostics.

• March 2025: Pharmaceutical and biotech firms expanded production of biomarker-based PoC kits to support early cancer screening.

Regional Insights
• Kanto Region - 42% share: Driven by "high concentration of advanced hospitals, rapid adoption of digital PoC platforms, and strong presence of leading diagnostics companies."

• Kansai Region - 24% share: Growth supported by "active medical research ecosystem, strong demand for PoC in chronic disease monitoring, and expansion of smart hospital projects."

• Chubu Region - 16% share: Expanding due to "increasing deployment of rapid testing devices in mid-sized hospitals and clinics."

• Kyushu & Okinawa - 10% share: Driven by "growing need for decentralized diagnostics and rising investment in primary care facilities."

• Hokkaido & Tohoku - 8% share: Growth supported by "higher demand for PoC solutions in rural and elderly populations requiring quick diagnostics."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/japan-point-of-care-diagnostics-market?sai-v

Key Segments

➥ By Product
Infectious disease testing products dominate the market as rapid detection of viral and bacterial infections becomes essential for timely treatment and outbreak control. Blood glucose products maintain strong demand driven by the rising prevalence of diabetes and the need for continuous, point-of-care monitoring. Blood gas & electrolyte testing products are widely used in critical care and emergency settings for immediate assessment of respiratory and metabolic conditions. Urinalysis products support routine diagnostics in hospitals and home-care environments, driving consistent adoption. Hematology testing products are crucial for blood disorder detection, anemia screening, and general health evaluation. Pregnancy and fertility testing products remain highly utilized due to their convenience, affordability, and accuracy for home-based testing. Tumor/cancer profiling products are expanding rapidly as oncology shifts toward personalized and early detection approaches. Drug-of-abuse testing products see strong usage in workplaces, law enforcement, and rehabilitation centers. Other products include multi-parameter kits and specialized diagnostics addressing emerging healthcare needs.

➥ By Technology
Lateral flow assays lead due to their simplicity, rapid results, and suitability for home testing and decentralized healthcare settings. Immunoassays remain widely used for high-sensitivity detection of biomarkers across infectious diseases, hormonal disorders, and chronic illnesses. Molecular diagnostics are the fastest-growing segment, driven by rising adoption of PCR, isothermal amplification, and next-generation sequencing for accurate detection of genetic material. Microfluidics technology is gaining traction as it enables compact, precise, and automated testing platforms for point-of-care applications. Other technologies include biosensors and advanced hybrid diagnostic tools that enhance speed, sensitivity, and connectivity.

➥ By Application
Infectious disease testing holds the largest share due to high demand for rapid diagnosis of respiratory infections, sexually transmitted infections, and emerging pathogens. Cardiology-related diagnostics are expanding with increasing cases of cardiovascular disorders requiring quick assessment. Oncology applications continue to rise as diagnostic tools support early detection, treatment selection, and therapy monitoring in cancer care. Endocrinology applications, especially diabetes and thyroid testing, remain essential in routine clinical practice. Hematology testing is widely used for complete blood counts and detection of blood-related disorders. Neurology applications grow with greater need for biomarkers detecting neurological diseases and cognitive impairments. Drug testing remains vital for forensic, workplace, and clinical use. Other applications include metabolic, gastrointestinal, and autoimmune disease diagnostics.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.